Takeda, a Japanese biopharmaceutical company, has entered into a strategic partnership with Hyderabad-based vaccine maker Biological E. to expedite the availability of the QDENGA dengue vaccine (TAK-003). This partnership was announced at the BioAsia 2024 inaugural session in Hyderabad in the presence of Chief Minister A. Revanth Reddy.
Biological E. aims to augment its manufacturing capacity to produce up to 50 million doses of the QDENGA vaccine annually. This collaboration aligns with Takeda’s goal to achieve an annual production capacity of 100 million doses within the next decade.
The partnership capitalizes on existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany, and leverages Takeda’s long-standing partnership with IDT Biologika GmbH.
TAK-003, also known as QDENGA, is a dengue tetravalent live, attenuated vaccine that is presently available for children and adults in the private markets of several countries, including in Europe, Indonesia, Thailand, Argentina, and Brazil. However, it is yet to receive approval for use in India.
The strategic collaboration between Takeda and Biological E. is expected to facilitate the accelerated production and potential availability of the dengue vaccine, ultimately contributing to the global efforts to address the impact of dengue fever.
The partnership is designed to leverage the strengths and capabilities of both companies to support the efficient manufacturing and distribution of the QDENGA vaccine, with the potential to enhance access to this critical healthcare intervention.
With this partnership, Takeda and Biological E. aim to further advance their commitment to public health by addressing the unmet medical needs related to dengue, particularly in regions with a high prevalence of the disease.
The joint endeavor underscores the significance of strategic collaborations in the pharmaceutical and biotechnology sector to bolster global health security and pandemic preparedness.
In conclusion, the partnership between Takeda and Biological E. reflects a concerted effort to harness expertise and resources, with the overarching objective of improving access to life-saving vaccines and strengthening the global response to infectious diseases.
